Company profile
Artiva Biotherapeutics, Inc.
NASDAQ:ARTVBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| AB-101 | phase1_2 | — | 3 | active |
| Anpocogin | phase1_2 | — | 1 | withdrawn |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05678205 | phase1_2 | withdrawn | 2023-08-01 | 2027-04-01 | Artiva Biotherapeutics, Inc. | A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors |
| NCT04673617 | phase1_2 | completed | 2021-03-29 | 2025-10-06 | Artiva Biotherapeutics, Inc. | AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma |
| NCT06265220 | phase1 | active_not_recruiting | 2024-04-03 | 2027-08-01 | Artiva Biotherapeutics, Inc. | AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus |
| NCT06991114 | phase2 | recruiting | 2025-07-09 | 2028-01-01 | Artiva Biotherapeutics, Inc. | AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases. |
FDA applications (0)
No records yet.